Targeted delivery of cisplatin to tumor xenografts via the nanoparticle component of nano-diamino-tetrac

Thangirala Sudha; Dhruba J. Bharali; Murat Yalcin; Noureldien H.E. Darwish; Melis Debreli Coskun; Kelly A. Keating; Hung Yun Lin; Paul J. Davis; Shaker A. Mousa

doi:10.2217/nnm-2016-0315

Targeted delivery of cisplatin to tumor xenografts via the nanoparticle component of nano-diamino-tetrac

Thangirala Sudha, Dhruba J. Bharali, Murat Yalcin, Noureldien H.E. Darwish, Melis Debreli Coskun, Kelly A. Keating, Hung Yun Lin, Paul J. Davis, Shaker A. Mousa

Research output: Contribution to journal › Article › peer-review

33 Citations (Scopus)

Abstract

Aim: Nano-diamino-tetrac (NDAT) targets a receptor on integrin αvβ3; αvβ3 is generously expressed by cancer cells and dividing endothelial cells and to a small extent by nonmalignant cells. The tetrac (tetraiodothyroacetic acid) of NDAT is covalently bound to a poly(lactic-co-glycolic acid) nanoparticle that encapsulates anticancer drugs. We report NDAT delivery efficiency of cisplatin to agent-susceptible urinary bladder cancer xenografts. Materials & methods: Cisplatin-loaded NDAT (NDAT-cisplatin) was administered to xenograft-bearing nude mice. Tumor size response and drug content were measured. Results: Intratumoral drug concentration was up to fivefold higher (p < 0.001) in NDAT-cisplatin-exposed lesions than with conventional systemic administration. Tumor volume reduction achieved was NDAT-cisplatin > NDAT without cisplatin > cisplatin alone. Conclusion: NDAT markedly enhances cisplatin delivery to urinary bladder cancer xenografts and increases drug efficacy.

Original language	English
Pages (from-to)	195-205
Number of pages	11
Journal	Nanomedicine
Volume	12
Issue number	3
DOIs	https://doi.org/10.2217/nnm-2016-0315
Publication status	Published - Feb 2017

Keywords

NDAT
cisplatin
integrin
nanotetrac
tetraiodothyroacetic acid
urinary bladder carcinoma

ASJC Scopus subject areas

Bioengineering
Medicine (miscellaneous)
Biomedical Engineering
General Materials Science

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/nnm-2016-0315

Cite this

@article{2d53cb84812b482c8390a282250d7068,

title = "Targeted delivery of cisplatin to tumor xenografts via the nanoparticle component of nano-diamino-tetrac",

abstract = "Aim: Nano-diamino-tetrac (NDAT) targets a receptor on integrin αvβ3; αvβ3 is generously expressed by cancer cells and dividing endothelial cells and to a small extent by nonmalignant cells. The tetrac (tetraiodothyroacetic acid) of NDAT is covalently bound to a poly(lactic-co-glycolic acid) nanoparticle that encapsulates anticancer drugs. We report NDAT delivery efficiency of cisplatin to agent-susceptible urinary bladder cancer xenografts. Materials & methods: Cisplatin-loaded NDAT (NDAT-cisplatin) was administered to xenograft-bearing nude mice. Tumor size response and drug content were measured. Results: Intratumoral drug concentration was up to fivefold higher (p < 0.001) in NDAT-cisplatin-exposed lesions than with conventional systemic administration. Tumor volume reduction achieved was NDAT-cisplatin > NDAT without cisplatin > cisplatin alone. Conclusion: NDAT markedly enhances cisplatin delivery to urinary bladder cancer xenografts and increases drug efficacy.",

keywords = "NDAT, cisplatin, integrin, nanotetrac, tetraiodothyroacetic acid, urinary bladder carcinoma",

author = "Thangirala Sudha and Bharali, {Dhruba J.} and Murat Yalcin and Darwish, {Noureldien H.E.} and Coskun, {Melis Debreli} and Keating, {Kelly A.} and Lin, {Hung Yun} and Davis, {Paul J.} and Mousa, {Shaker A.}",

note = "Publisher Copyright: {\textcopyright} 2017 Paul J. Davis.",

year = "2017",

month = feb,

doi = "10.2217/nnm-2016-0315",

language = "English",

volume = "12",

pages = "195--205",

journal = "Nanomedicine",

issn = "1743-5889",

publisher = "Future Medicine Ltd.",

number = "3",

}

TY - JOUR

T1 - Targeted delivery of cisplatin to tumor xenografts via the nanoparticle component of nano-diamino-tetrac

AU - Sudha, Thangirala

AU - Bharali, Dhruba J.

AU - Yalcin, Murat

AU - Darwish, Noureldien H.E.

AU - Coskun, Melis Debreli

AU - Keating, Kelly A.

AU - Lin, Hung Yun

AU - Davis, Paul J.

AU - Mousa, Shaker A.

PY - 2017/2

Y1 - 2017/2

N2 - Aim: Nano-diamino-tetrac (NDAT) targets a receptor on integrin αvβ3; αvβ3 is generously expressed by cancer cells and dividing endothelial cells and to a small extent by nonmalignant cells. The tetrac (tetraiodothyroacetic acid) of NDAT is covalently bound to a poly(lactic-co-glycolic acid) nanoparticle that encapsulates anticancer drugs. We report NDAT delivery efficiency of cisplatin to agent-susceptible urinary bladder cancer xenografts. Materials & methods: Cisplatin-loaded NDAT (NDAT-cisplatin) was administered to xenograft-bearing nude mice. Tumor size response and drug content were measured. Results: Intratumoral drug concentration was up to fivefold higher (p < 0.001) in NDAT-cisplatin-exposed lesions than with conventional systemic administration. Tumor volume reduction achieved was NDAT-cisplatin > NDAT without cisplatin > cisplatin alone. Conclusion: NDAT markedly enhances cisplatin delivery to urinary bladder cancer xenografts and increases drug efficacy.

AB - Aim: Nano-diamino-tetrac (NDAT) targets a receptor on integrin αvβ3; αvβ3 is generously expressed by cancer cells and dividing endothelial cells and to a small extent by nonmalignant cells. The tetrac (tetraiodothyroacetic acid) of NDAT is covalently bound to a poly(lactic-co-glycolic acid) nanoparticle that encapsulates anticancer drugs. We report NDAT delivery efficiency of cisplatin to agent-susceptible urinary bladder cancer xenografts. Materials & methods: Cisplatin-loaded NDAT (NDAT-cisplatin) was administered to xenograft-bearing nude mice. Tumor size response and drug content were measured. Results: Intratumoral drug concentration was up to fivefold higher (p < 0.001) in NDAT-cisplatin-exposed lesions than with conventional systemic administration. Tumor volume reduction achieved was NDAT-cisplatin > NDAT without cisplatin > cisplatin alone. Conclusion: NDAT markedly enhances cisplatin delivery to urinary bladder cancer xenografts and increases drug efficacy.

KW - NDAT

KW - cisplatin

KW - integrin

KW - nanotetrac

KW - tetraiodothyroacetic acid

KW - urinary bladder carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85010383217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010383217&partnerID=8YFLogxK

U2 - 10.2217/nnm-2016-0315

DO - 10.2217/nnm-2016-0315

M3 - Article

AN - SCOPUS:85010383217

SN - 1743-5889

VL - 12

SP - 195

EP - 205

JO - Nanomedicine

JF - Nanomedicine

IS - 3

ER -

Targeted delivery of cisplatin to tumor xenografts via the nanoparticle component of nano-diamino-tetrac

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this